Phoenix Bio

R&D OVERVIEW

R&D OVERVIEW

A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

    Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

    Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection

      Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.

      Gastroenterology. 2017 Oct 24. pii: S0016-5085(17)36276-5. doi: 10.1053/j.gastro.2017.10.017.

      Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

        Sato, Y. Matsui, H. Yamamoto, N. Sato, R. Munakata, T. Kohara, M. Harashima, H.

        J Control Release. 2017 Oct 3;266:216-225. doi: 10.1016/j.jconrel.2017.09.044.

        Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages

          Cheng, X. Xia, Y. Serti, E. Block, P. D. Chung, M. Chayama, K. Rehermann, B. Liang, T. J.

          Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.

          Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

            Tsuge, M. Uchida, T. Hiraga, N. Kan, H. Makokha, G. N. Abe-Chayama, H. Miki, D. Imamura, M. Ochi, H. Hayes, C. N. Shimozono, R. Iwamura, T.Narumi, H. Suzuki, T  Kainoh, M. Taniguchi, T. Chayama, K.

            Antimicrob Agents Chemother. 2017 May 24;61(6).

            The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection

              Niu, C. Livingston, C. M. Li, L. Beran, R. K. Daffis, S. Ramakrishnan, D. Burdette, D. Peiser, L. Salas, E. Ramos, H. Yu, M. Cheng, G. Strubin, M. Delaney Iv, W. E. Fletcher, S. P.

              PLoS One. 2017 Jan 17;12(1):e0169648.

              Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

                Decorsiere, A. Mueller, H. van Breugel, P. C. Abdul, F. Gerossier, L. Beran, R. K. Livingston, C. M. Niu, C. Fletcher, S. P. Hantz, O. Strubin, M.

                Nature. 2016 Mar 17;531(7594):386-9. doi: 10.1038/nature17170.

                Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice

                  Uchida, T. Imamura, M. Hayes, C. N. Hiraga, N. Kan, H. Tsuge, M. Abe-Chayama, H. Zhang, Y. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                  Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00725-17. doi: 10.1128/AAC.00725-17

                  Transmission of HBV DNA Mediated by Ceramide-Triggered Extracellular Vesicles

                    Sanada,Takahiro1,*  Hirata, Yuichi1,* Naito, Yutaka 2,  Yamamoto,Naoki1,  Kikkawa, Yoshiaki3, Ishida, Yuji 4,  Yamasaki,Chihiro 4,  Tateno, Chise 4,  Ochiya, Takahiro 2 and  Kohara, Michinori 1

                    Cell Mol Gastroenterol Hepatol. 2016 Oct 24;3(2):272-283.

                    Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity

                      Shimura, S. Watashi, K. Fukano, K. Peel, M. Sluder, A. Kawai, F. Iwamoto, M. Tsukuda, S. Takeuchi, J. S. Miyake, T. Sugiyama, M. Ogasawara, Y. Park, S. Y. Tanaka, Y. Kusuhara, H. Mizokami, M. Sureau, C. Wakita, T.

                      J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30683-3. doi: 10.1016/j.jhep.2016.11.009.